Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision

Annals of Surgical Oncology

Volumn 18, Issue 13, 2011, Pages 3666-3672

  Govindarajan, Anand ^a   Reidy, Diane ^a   Weiser, Martin R ^a   Paty, Philip B ^a   Temple, Larissa K ^a   Guillem, Jose G ^a   Saltz, Leonard B ^a   Wong, W Douglas ^a   Nash, Garrett M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PROGNOSIS; RECTUM CANCER; RECTUM SURGERY; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TOTAL MESORECTAL EXCISION; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 82955233576     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1788-y     Document Type: Article

References (23)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-rectal cancer, 2010. http://www.nccn.org/.
2. R Sauer H Becker W Hohenberger, et al. 2004 Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med. 351 1731 1740 15496622 10.1056/NEJMoa040694 1:CAS:528:DC%2BD2cXovFSksbo%3D (Pubitemid 39383208)
3. C Capirci V Valentini L Cionini, et al. 2008 Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients Int J Radiat Oncol Biol Phys. 72 99 107 18407433 10.1016/j.ijrobp.2007.12.019
4. GJ Chang MA Rodriguez-Bigas C Eng JM Skibber 2009 Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome Cancer. 115 5432 5440 19673001 10.1002/cncr.24622
5. P Das JM Skibber MA Rodriguez-Bigas, et al. 2006 Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer Am J Clin Oncol. 29 219 224 16755173 10.1097/01.coc.0000214930.78200.4a (Pubitemid 44270928)
6. LJ Kuo MC Liu JJ Jian, et al. 2007 Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol. 14 2766 2772 17551794 10.1245/s10434-007-9471-z (Pubitemid 47460637)
7. HM Quah JF Chou M Gonen, et al. 2008 Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation Cancer. 113 57 64 18442099 10.1002/cncr.23516 (Pubitemid 351976386)
8. M Maas PJ Nelemans V Valentini, et al. 2010 Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data Lancet Oncol. 11 835 844 20692872 10.1016/S1470-2045(10)70172-8
9. F Stipa DB Chessin J Shia, et al. 2006 A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography Ann Surg Oncol. 13 1047 1053 16865595 10.1245/ASO.2006.03.053 (Pubitemid 44337963)
10. Jessup JM, Gunderson LL, al FLGe. Colon and rectum. In: Greene FL, Page AL, Fleming ID, editors. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. p. 113-24.
11. WE Enker HT Thaler ML Cranor T Polyak 1995 Total mesorectal excision in the operative treatment of carcinoma of the rectum J Am Coll Surg. 181 335 346 7551328 1:STN:280:DyaK28%2FgvVCksw%3D%3D
12. RJ Heald BJ Moran RD Ryall R Sexton JK MacFarlane 1998 Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997 Arch Surg. 133 894 899 9711965 10.1001/archsurg.133.8.894 1:STN:280:DyaK1cznsFOrsQ%3D%3D (Pubitemid 28374285)
13. A de Gramont JF Bosset C Milan, et al. 1997 Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study J Clin Oncol. 15 808 815 9053508 (Pubitemid 27074252)
14. T Andre C Boni M Navarro, et al. 2009 Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol. 27 3109 3116 19451431 10.1200/JCO.2008.20.6771 1:CAS:528:DC%2BD1MXhtFWitbzF
15. JP Kuebler HS Wieand MJ O'Connell, et al. 2007 Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 J Clin Oncol. 25 2198 2204 17470851 10.1200/JCO.2006.08.2974 1:CAS:528:DC%2BD2sXnsVShtL0%3D (Pubitemid 46954643)
16. D Sargent A Grothey 2007 Sound footing or slippery slope? The value of secondary analyses of randomized trials J Clin Oncol. 25 3191 3193 17664465 10.1200/JCO.2007.11.5089 (Pubitemid 47325600)
17. JF Bosset L Collette G Calais, et al. 2006 Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med. 355 1114 1123 16971718 10.1056/NEJMoa060829 1:CAS:528:DC%2BD28XpsFKkur8%3D (Pubitemid 44394918)
18. AC Ashley DJ Sargent SR Alberts, et al. 2007 Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in first-line treatment of metastatic colorectal cancer Cancer. 110 670 677 17559146 10.1002/cncr.22831 1:CAS:528:DC%2BD2sXpt1yqu7c%3D (Pubitemid 47106158)
19. SR Land JA Kopec RS Cecchini, et al. 2007 Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07 J Clin Oncol. 25 2205 2211 17470850 10.1200/JCO.2006.08.6652 1:CAS:528:DC%2BD2sXnsVShtLk%3D (Pubitemid 46954644)
20. S Sharif MJ O'Connell G Yothers S Lopa N Wolmark 2008 FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer Cancer Invest. 26 956 963 18798075 10.1080/07357900802132550 1:CAS:528:DC%2BD1cXhsVCms7%2FN
21. L Collette JF Bosset M den Dulk, et al. 2007 Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group J Clin Oncol. 25 4379 4386 17906203 10.1200/JCO.2007.11.9685 1:CAS:528:DC%2BD2sXht1ertrjO (Pubitemid 350013843)
22. VR Muthusamy KJ Chang 2007 Optimal methods for staging rectal cancer Clin Cancer Res 13 22 Pt 2 6877s 6884s 18006793 10.1158/1078-0432.CCR-07-1137
23. A Rullier C Laurent M Capdepont, et al. 2008 Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status, and impact on survival Am J Surg Pathol. 32 45 50 18162769 10.1097/PAS.0b013e3180dc92ab